Ann: Completion of Enrolment in SMARTCOUGH-C Study, page-48

IMO the Agar Plate reading tech is great.
There is no comparison to the immediate post FDA approval for potential income of Resapp with worldwide Pediatric use alone.
RAP does not have to manufacture anything.
No holes to dig.
No exploratory wells to dig.
No awaiting on a Phase 2 clinical trial of an unknown drug then having to run a Phase 3 2000 - 3000 patient clinical trial at a cost of millions and multiple share dilutions with Capital Raising and consolidations.
And after the Phase 3 a 52 week safety period...

RAP 2 years from listing to most probable great FDA clinical approval of a revolution in respiratory diagnosis for the most common reason a person goes to the doctor world wide!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

RAP is amazing and the boys are waiting in the wings for these results.

These awaiting results when mirroring the Australian clinical trials are not only derisking for Pediatric FDA approval, they give indication of further potential of Adult use approval and potential income from Adult approval.

I see....

The potential for pediatric use of Resapp for pediatric use in RAP's 1st full financial quarter ending December 2017 being wonderful.
This is when the share price will go into Warp drive.
Then the added potential income with adult use, will be amazing to share price.

October 2017 world media will spread news of FDA approval of Resapp respiratory better than hospital medical experts diagnosis mobile phone app.

More world media in November 2017 Doctors Without Borders approve Resapp for use by all humanitarian organizations and sign a 10 million per year fee.

I see Apple health, Samsung Health, AmWell, and many telehealth providers worldwide, I see Massachusetts General Hospital, Texas Childrens Hospital, Cleveland General Hospital (With direct line to Congress) and many hospitals throughout the US and worldwide using Resapp

The market interest in RAP's potential will be realized on RAP's balance sheet end of December 2017.
Commercialization of a product that is essential, must have, for use in telehealth and hospitals worldwide.
The potential cost savings that RAP's approved diagnostic tool brings to health care budgets is staggering.
RAP is beyond all estimations of growth and potential share price estimations.

FIL knows it and so do many others.
With great results soon to be released the escrow shares will be like milk and honey for funds like FIL and RAP share price will head north amazing all share holders.

RAP is a digital revolution about to happen.
Wow...I love it.

There has been nothing but positive momentum with RAP and it just gets better all the time.
My words are my own personal good feelings and I always get what I think every time.

Luv RAP
MB